drugset / Trial / NCT02949726
Lymphatic and Systemic Immunity Changes in Post-radiation Lymphedema Development
Phase 1
Completed
80 enrolled
The University of Texas Health Science Center, Houston
M.D. Anderson Cancer Center · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelBasic science
Summary
The goal of this study is to find out which immune molecules, cells, and genes are involved in the development of lymphedema (LE), so that medicines that target them can be considered for treating lymphedema. The hypothesis is that LE is a systemic, autoimmune-like disease that is initiated by inflammatory cytokines induced by surgery, radiation, and possibly chemotherapy in genetically susceptible patients.
Timeline
- Start
- 2017-04-24
- Primary completion
- 2022-10-01
- Completion
- 2022-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Indocyanine Green | Diagnostic / imaging agent | — | — |